A Pharmacodynamic Study With Ticagrelor in African American Patients

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in African American patients with stable coronary artery disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Clopidogrel; Ticagrelor; Ticlopidine

Criteria

Inclusion Criteria:

• Provision of signed and dated informed consent before initiation of any study-related procedures

• Male or female patients aged 18 years or older

• Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment

• Females must be post menopausal or surgically sterile Self-identified as African American

Exclusion Criteria:

• Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period

• Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment

• Current smokers, including the use of tobacco containing products in the past 1 month of randomization Patients required dialysis